Parkinson Disease: Multimedia

References

1. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med. Oct 8 1998;339(15):1044-53. [Medline].

2. Stoessl AJ. Etiology of Parkinson's disease. Can J Neurol Sci. Aug 1999;26 Suppl 2:S5-12. [Medline].

3. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med. Oct 15 1998;339(16):1130-43. [Medline].

4. Driver JA, Logroscino G, Gaziano JM, et al. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. Feb 3 2009;72(5):432-8. [Medline].

5. Grimes DA, Lang AE. Treatment of early Parkinson's disease. Can J Neurol Sci. Aug 1999;26 Suppl 2:S39-44. [Medline].

6. Thobois S, Delamarre-Damier F, Derkinderen P. Treatment of motor dysfunction in Parkinson's disease: an overview. Clin Neurol Neurosurg. Jun 2005;107(4):269-81. [Medline].

7. Stoessl AJ, Rivest J. Differential diagnosis of parkinsonism. Can J Neurol Sci. Aug 1999;26 Suppl 2:S1-4. [Medline].

8. Tolosa E, Gaig C, Santamaria J, et al. Diagnosis and the premotor phase of Parkinson disease. Neurology. Feb 17 2009;72(7 Suppl):S12-20. [Medline].

9. Sliwa JA. Neuromuscular rehabilitation and electrodiagnosis. 1. Central neurologic disorders. Arch Phys Med Rehabil. Mar 2000;81(3 Suppl 1):S3-12; quiz S36-44. [Medline].

10. Dombovy ML. Rehabilitation concerns in degenerative movement disorders of the central nervous system. In: Braddom RL, ed. Handbook of Physical Medicine and Rehabilitation. Philadelphia, Pa: WB Saunders; 1996:1088-99.

11. Honey C, Gross RE, Lozano AM. New developments in the surgery for Parkinson's disease. Can J Neurol Sci. Aug 1999;26 Suppl 2:S45-52. [Medline].

12. Chu J, Wagle-Shukla A, Gunraj C, et al. Impaired presynaptic inhibition in the motor cortex in Parkinson disease. Neurology. Mar 3 2009;72(9):842-9. [Medline].

13. Fogelson N, Kühn AA, Silberstein P, et al. Frequency dependent effects of subthalamic nucleus stimulation in Parkinson's disease. Neurosci Lett. Jul 1-8 2005;382(1-2):5-9. [Medline].

14. Poewe W. Treatments for Parkinson disease--past achievements and current clinical needs. Neurology. Feb 17 2009;72(7 Suppl):S65-73. [Medline].

15. Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology. Feb 17 2009;72(7 Suppl):S44-50. [Medline].

16. Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. Feb 2009;66(2):167-72. [Medline].

17. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. 25^th ed. Toronto, Canada: Webcom Ltd; 2000.

Further Reading

Keywords

Parkinson's disease, Parkinson disease, Parkinson, tremors, tremor, dopamine, Parkinson's, deep brain stimulation, motor cortex, Parkinson's symptoms, dementia, L dopa, movement disorders, Parkinson's treatment, Parkinson's disease symptoms, parkinsonism, levodopa, bradykinesia, Parkinson's disease treatment, Parkinson disease symptoms, L-dopa, idiopathic Parkinson disease

Contributor Information and Disclosures

Author

Jeff Blackmer, MD, FRCP(C), Associate Professor, Medical Director, Neurospinal Service, Division of Physical Medicine and Rehabilitation, The Rehabilitation Centre; Executive Director, Office of Ethics, Canadian Medical Association
Jeff Blackmer, MD, FRCP(C) is a member of the following medical societies: American Paraplegia Society, Canadian Association of Physical Medicine and Rehabilitation, Canadian Medical Association, and Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.

Medical Editor

Milton J Klein, DO, MBA, Consulting Physiatrist, Heritage Valley Health System-Sewickley Hospital, Allegheny General Hospital, and Ohio Valley General Hospital.
Milton J Klein, DO, MBA is a member of the following medical societies: American Academy of Disability Evaluating Physicians, American Academy of Medical Acupuncture, American Academy of Osteopathy, American Academy of Physical Medicine and Rehabilitation, American Medical Association, American Osteopathic Association, American Osteopathic College of Physical Medicine and Rehabilitation, American Pain Society, and Pennsylvania Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Kat Kolaski, MD, Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine
Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

CME Editor

Kelly L Allen, MD, Regional Medical Director, IMX-Medical Management Services
Disclosure: Nothing to disclose.

Chief Editor

Denise I Campagnolo, MD, MS, Director of Multiple Sclerosis Clinical Research and Staff Physiatrist, Barrow Neurology Clinics, St Joseph's Hospital and Medical Center; Investigator for Barrow Neurology Clinics; Director, NARCOMS Project for Consortium of MS Centers
Denise I Campagnolo, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Association of Neuromuscular and Electrodiagnostic Medicine, American Paraplegia Society, Association of Academic Physiatrists, and Consortium of Multiple Sclerosis Centers
Disclosure: Teva Neuroscience Honoraria Speaking and teaching; Serono-Pfizer Honoraria Speaking and teaching